MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Efficacy and Safety of Different Apomorphine Formulations for OFF Episodes in Parkinson’s Disease: A Systematic Review and Meta-Analysis

    A. Abunamoos, M. Alghaniem, Y. Aljazi, F. Alnajjar, A. Al-Qudah, Q. Abulawi, M. Mustafa (Amman, Jordan)

    Objective: To assess the efficacy and safety of different apomorphine formulations for managing OFF episodes in Parkinson’s disease (PD) through a systematic review and meta-analysis.…
  • 2025 International Congress

    A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the NLRP3 Inhibitor Vent-02 in Patients with Mild to Moderate Parkinson’s Disease

    A. Matta, X. Valencia, K. Pike, L. Warner, O. Spiegelstein, M. Bigal (Waltham, USA)

    Objective: To describe the innovative Phase 2 study design aimed to investigate vent-02 in the treatment of PD. Background: NLRP3 hyperactivation plays a critical role…
  • 2025 International Congress

    Gait Imagination and Gait Observation Related Midfrontal Oscillations in People With Parkinson’s Disease and Freezing of Gait

    A. Singh, M. Leedom (Vermillion, USA)

    Objective: To examine midfrontal oscillations in people with Parkinson’s disease (PD) with freezing of gait (PDFOG+), without FOG (PDFOG–), and healthy controls during gait imagination…
  • 2025 International Congress

    Targeting IGF2 Signaling for Immune Modulation of Microglia in Parkinson’s Disease

    T. Huerta, V. Urbina, C. Aguilera, P. Chana, R. Vidal (Santiago, Chile)

    Objective: We propose that IGF2 induces a distinct inflammatory phenotype in macrophages or microglia derived from Parkinson’s disease (PD) patients. Background: Microglia are the resident…
  • 2025 International Congress

    Functional Activity of Apomorphine Relative to Dopamine at Dopamine Receptors: Findings from G Protein Coupled Receptor Biosensor Assays

    B. Yegla, P. Jenner, M. Grall, J. Rubin (Rockville, USA)

    Objective: Characterize the functional activity of apomorphine relative to dopamine using a modern panel of G protein-coupled receptor biosensor assays. Background: The structural similarity of…
  • 2025 International Congress

    The Effects of Melatonin in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Double-Blind, Placebo-Controlled RCTs

    V. Byroju, J. Pitton Rissardo, A. Fornari Caprara (Camden, USA)

    Objective: To assess the efficacy of melatonin on motor symptoms, sleep quality, and quality of life in patients with Parkinson's disease (PD) by performing a…
  • 2025 International Congress

    Neuroprotection on the Horizon: Are GLP-1 Receptor Agonists the Next Breakthrough in Parkinson’s Disease?

    M. Helal, H. Aboushawareb, O. Hussein Abbas, R. Haddad, Y. Zain, A. S.A Osman, N. Hamam, A. Hassan (Zagazig, Egypt)

    Objective: This meta-analysis evaluates the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with Parkinson’s disease (PD). Background: Epidemiological studies suggest an increased…
  • 2025 International Congress

    A case of Parkinson’s Disease whose Daily Levodopa/Carbidopa Intestinal Gel dose has been determined by her spouse and prevented Long-term Fluctuations

    Y. Okuma (Izunokuni, Japan)

    Objective: To present a case of Parkinson’s disease (PD) whose daily levodopa/carbidopa intestinal gel (LCIG) dose has been determined by her spouse and prevented long-term…
  • 2025 International Congress

    Mortality and Institutionalisation Following de Novo Use of Rotigotine Patches in Hospitalised Patients with Parkinson’s Disease

    E. Kaye, K. Millington, R. Skelly (Nottingham, United Kingdom)

    Objective: Guidelines recommend use of rotigotine patches as an option if Parkinson’s patients are unable to take their usual oral medication, but this strategy has…
  • 2025 International Congress

    Anti-Parkinsonian effects of Globimetula cupulata leaf extract and its underlying mechanisms in 6-hydroxydopamine-lesioned rat model

    A. Hamadjida, R. Ayissi Mbomo, S. Minko, F. Ntchapda, J. Mingoas Kilekoung (BERTOUA, Cameroon)

    Objective: To evaluate the neuroprotective effects of Globimetula cupulata in a rat model of Parkinson Disease (PD) induced by 6-hydroxydopamine (6-OHDA) injection in the striatum,…
  • « Previous Page
  • 1
  • …
  • 165
  • 166
  • 167
  • 168
  • 169
  • …
  • 181
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley